DIAGNOSTIC CRITERIA FOR LOCALIZED SCLERODERMA

Authors:

Abstract:

Localized scleroderma remains a complex diagnostic challenge due to diverse clinical manifestations and a lack of prognostic markers. A study of 113 individuals analyzed demographic, clinical, and laboratory parameters, including vascular endothelial growth factor levels, to assess vascular dysfunction. The disease demonstrates significant gender and age specificity, with onset peaks among young men and older women. Most lesions are plaque forms at the induration stage, indicating late clinical detection. Vascular endothelial growth factor has been shown to be an objective severity indicator, correlating directly with the extent of fibrosis. Based on these results, a novel multilevel prognostic model was developed that integrates risk factors, morphology, and angiogenesis markers. This model holds significant value for global dermatology, enabling the timely identification of high-risk patients, predicting the clinical course, and preventing irreversible tissue changes through early, personalized treatment.

Keywords:

localized scleroderma vascular endothelial growth factor prognostic model disease severity endothelial dysfunction risk factors

References:

1. Andersen LK, Davis MDP. Prevalence of Skin and Skin-Related Diseases in the Rochester Epidemiology Project and a Comparison with Other Published Prevalence Studies. Dermatology. 2016;232(3):344–52.doi: 10.1159/000444580.
2. Asano Y, Fujimoto M, Ishikawa O, Sato S, Jinnin M, Takehara K, et al. Diagnostic criteria, severity classification and guidelines of localized scleroderma. The Journal of Dermatology. 2018 Apr;45(7):755–80.doi: 10.1111/1346-8138.14161.
3. Bali G, Szilvási A, Inotai D, Varga Á, Sárdy M, Kárpáti S, et al. Comorbidity of localized scleroderma and primary biliary cholangitis. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2018 Nov;16(11):1323–7. doi: 10.1111/ddg.13693.
4. Calderon LM, Pope JE. Scleroderma epidemiology update. Curr Opin Rheumatol. 2021;33(2):122-127. doi:10.1097/BOR.0000000000000785.
5. Distler O, Cozzio A. Systemic sclerosis and localized scleroderma: current concepts and novel targets for therapy. Seminars in Immunopathology. 2016;38(1):87–95. doi:10.1007/s00281-015-0520-3.
6. George R, George A, Kumar TS. Update on Management of Morphea (Localized Scleroderma) in Children. Indian Dermatology Online Journal [Internet]. 2020 Mar 9 [cited 2021 May 26];11(2):135–45. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247622/.
7. Li Z, Xiao Y, Kang L, et al. Comparative Study of Adipose-Derived Stem Cells from Localized Scleroderma Patients and Healthy Donors in Treating Skin Fibrosis. Plast Reconstr Surg. 2025;155(4):716e-726e. doi:10.1097/PRS.0000000000011779.
8. Kreuter A, Moinzadeh P, Kinberger M, et al. S2k guideline: Diagnosis and therapy of localized scleroderma. J Dtsch Dermatol Ges. 2024;22(4):605-620. doi:10.1111/ddg.15328.
9. Moinzadeh P, Hunzelmann N, Kreuter A, Krieg T. Localized scleroderma: a review. Journal of Scleroderma and Related Disorders. 2016;1(3):286–97.https://doi.org/10.5301/jsrd.5000215.
10. Penmetsa GK, Sapra A. Morphea [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559010/.
11. Rodríguez-Salgado P, García-Romero MT. Morphea: a practical review of its diagnosis, classification and treatment. Gac Med Mex. 2019;155(5):483-491. doi:10.24875/GMM.M20000336
12. Rongioletti F, Ferreli C, Atzori L, Bottoni U, Soda G. Scleroderma with an update about clinico-pathological correlation. G Ital Dermatol Venereol. 2018;153(2):208-215. doi:10.23736/S0392-0488.18.05922-9.
13. Shenavandeha S., Eskandar T. T., Nazariniaad K. S. M. Serum vascular endothelial growth factor (VEGF), soluble VEGF receptor-1 (sVEGFR-1) and sVEGFR-2 in systemic sclerosis patients: Relation to clinical manifestations and capillaroscopy findings. The Egyptian Rheumatologist. 2017; 39 (1): 19-24.
14. Tsou Pei Suen, Sawalha AH. Unfolding the pathogenesis of scleroderma through genomics and epigenomics. Journal of Autoimmunity [Internet]. 2017 Sep;83:73–94. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573604/.
15. Zhao M, Wu J, Wu H, Sawalha AH, Lu Q. Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review. Clin Rev Allergy Immunol. 2022;62(2):273-291. doi:10.1007/s12016-020-08831-4.

Publication:

«World of Medicine and Biology» Vol. 22 No. 96 (2026) , с. 16-21
УДК 616.5-004-07:616-037

DOI:

https://doi.org/10.26724/2079-8334-2026-2-96-16-21